Linked Life Data

10853462

Source:http://linkedlifedata.com/resource/pubmed/id/10853462

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2000-9-13
pubmed:abstractText
Approximately 54,400 new cases of transitional cell carcinoma of the bladder were reported in the United States in 1999, with an estimated 12,500 deaths attributable to this cancer. Close to 75% of all bladder tumors are confined to the urothelium (stage Ta, or carcinoma in situ), and nearly 30% of papillary tumors invade the lamina propria (stage T1). The majority of superficial tumors are low grade with low rates of progression. Transurethral resection is the standard initial treatment for transitional cell carcinoma. Intravesical therapy is an important adjunct to transurethral resection in patients with superficial bladder cancer, many of whom are at risk for disease recurrence and progression. Cytotoxic and immunomodulating agents and, more recently, photosensitizers have demonstrated utility against superficial transitional cell carcinoma. Many studies have assessed and continue to examine the efficacy of various agents at different doses and in different combinations and schedules. Recently, valrubicin (Valstar) won Food and Drug Administration (FDA) approval only for the treatment of refractory carcinoma in situ. However, bacillus Calmette-Guérin (BCG) and mitomycin (Mutamycin) remain the most commonly used, most effective agents available for prophylaxis against recurrence and subsequent progression of superficial bladder cancer. This article reviews traditional and alternative intravesical agents useful in the therapy and prophylaxis of superficial transitional cell carcinoma of the bladder.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0890-9091
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
719-29; discussion 729-31, 734, 737
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10853462-Adjuvants, Immunologic, pubmed-meshheading:10853462-Administration, Intravesical, pubmed-meshheading:10853462-Antibiotics, Antineoplastic, pubmed-meshheading:10853462-Anticarcinogenic Agents, pubmed-meshheading:10853462-Antineoplastic Agents, pubmed-meshheading:10853462-Carcinoma, Transitional Cell, pubmed-meshheading:10853462-Doxorubicin, pubmed-meshheading:10853462-Epirubicin, pubmed-meshheading:10853462-Humans, pubmed-meshheading:10853462-Interferons, pubmed-meshheading:10853462-Mitomycin, pubmed-meshheading:10853462-Mycobacterium bovis, pubmed-meshheading:10853462-Neoplasm, Residual, pubmed-meshheading:10853462-Photochemotherapy, pubmed-meshheading:10853462-Photosensitizing Agents, pubmed-meshheading:10853462-Thiotepa, pubmed-meshheading:10853462-Urinary Bladder Neoplasms
pubmed:year
2000
pubmed:articleTitle
Intravesical therapy for superficial bladder cancer.
pubmed:affiliation
Department of Urology, Temple University Hospital, Philadelphia, Pennsylvania, USA.
pubmed:publicationType
Journal Article, Review